Making Earlier Detection of Ovarian Cancer a Reality

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker.

Cleo's first test - AdnexaSure^TM is designed to distinguish benign from malignant growths and will be compatible with standard diagnostic laboratory workflows worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted in over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, Cleo has a worldwide exclusive licence to commercialise the intellectual property underpinning its operations and the ovarian cancer tests.

Cleo is advancing the availability of its simple blood test, under a modular execution strategy to ultimately address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.